Lu X.-D.,Central Laboratory of Henan Tumor Hospital |
Fan R.-H.,Central Laboratory of Henan Tumor Hospital |
Hu J.-Y.,Central Laboratory of Henan Tumor Hospital |
Xu B.-L.,Central Laboratory of Henan Tumor Hospital |
And 4 more authors.
Journal of Xi'an Jiaotong University (Medical Sciences) | Year: 2010
Objective: To evaluate the significance of Ph chromosome and bcr-abl mRNA expressions in diagnosis, staging and treatment of chronic myeloid leukemia (CML) as well as in monitoring minimal residual disease. Methods: Expressions of Ph chromosome and bcr-abl mRNA of 437 CML patients were detected at the same time. Results: Expression of bcr-abl mRNA gradually increased in blastic phase (BP), accelerated phase (AP) and chronic phase (CP) (P < 0.05). Quantification of bcr-abl mRNA decreased gradually after allotransplantation in the patients, and it became normal after 6 months' treatment. However, quantification of bcr-abl mRNA in imatinib mesylate-treated patients did not become normal until longer time later. Conclusion: RT-PCR quantitative detection of bcr-abl mRNA is more sensitive than detection of Ph chromosome, and has an important clinical value in staging CML, monitoring treatment outcome, detecting the minimal residual disease and predicting disease development.